An interventional study of Diet-induced low energy availability and Exercise-induced low energy availability in Relative Energy Deficiency in Sport, sponsored by Australian Catholic University. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by Australian Catholic University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to understand how the body responds to short-term, severe low energy availability (LEA) in healthy, weight-bearing endurance athletes aged 18-45 years old. LEA describes a mismatch between an individual's dietary energy intake and the energy cost of their commitments for training and competition. The main questions this trial aims to answer are:
Researchers will compare a control trial with both a LEA trial achieved through diet restriction and a LEA trial achieved through increased exercise to see if there are differences in the body's response.
Participants will complete three 6-day trials, a minimum of 3-weeks apart, involving:
The study will involve a three-sequence crossover design, with participants undertaking a control trial first, involving energy availability of 40 kcal/kg fat free mass (FFM) and a 15 kcal/kg FFM exercise energy expenditure (EEE) as baseline training volume, before a counterbalanced allocation to low energy availability via dietary restriction (LEADIET) or low energy availability via increased exercise energy expenditure (LEAEX). This design will allow further screening of Relative Energy Deficiency in Sport (REDs) risk, identify participants who are likely to be unable to fulfil the exercise commitments of LEAEX and avoid the unknown carryover effects of two consecutive low energy availability (LEA) trials on the subsequent control trial, as would occur in some participants with a fully counterbalanced treatment allocation.
Baseline testing (body composition/bone mineral density via DXA, aerobic capacity, LEA hormone blood panel, vitamin D, resting metabolic rate, REDs screening via REDs-CAT2) will be undertaken to confirm inclusion and develop individualised diet and training plans. Thereafter, participants will undertake a 6-day supervised exposure to energy availability of \~40 kcal/kg FFM/d, involving supplied meals and prescribed daily running/race walking. For female participants, trials will commence within days 1-5 of the menstrual cycle, to ensure that all testing occurs in the same (follicular) phase. A minimum 3-week washout period will occur between trials, with participants being guided to return to habitual training and dietary habits. Trials 2 and 3 will consist of exposure to severe LEA (15 kcal/kg FFM/d), which is achieved either by superimposing restricted energy intake (EI) or increased (doubled) EEE on the previous training plan.
Diet plans and food provision will be managed by experienced sports dietitians to incorporate individual preferences and intolerances. While participants are free-living at the start of each trial week, food drops will be undertaken to check well-being and compliance to the diet/ training intervention. The final 2 days of residence at ACU facilities (medical unit and metabolic chamber) will allow more comprehensive data collection. Individual protocols (described briefly below) have been previously developed by our group and collaborators. Together, they will investigate within and between trial changes in metrics representing the range of body systems that have been identified at risk of perturbations due to LEA within the REDs Conceptual Health and Performance Models.
Summary of the protocols completed in this study:
Venepuncture/Venous cannulation: Total blood volume per trial = 140 ml for:
20 studies on the registry are indexed under Relative Energy Deficiency in Sport; 9 are open to participants now.
This study's planned enrollment of 20 is below the median of 28 across 10 interventional studies indexed under Relative Energy Deficiency in Sport.
Browse Relative Energy Deficiency in Sport studies →Australian Catholic University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 6-day control trial. All participants will commence with this trial involving an energy availability of 40 kcal/kg fat-free mass (FFM). Energy intake will be 55 kcal/kg FFM/d and exercise energy expenditure will be 15 kcal/kg FFM/d. This will be followed by a minimum 3-week washout period where the participant will be advised to return to their routine diet and exercise.
A 6-day severe low energy availability (LEA, 15kcal/kg FFM/d) trial, achieved by superimposing restricted energy intake on the HEA trial. Energy intake will be 30 kcal/kg FFM/d and exercise energy expenditure will be 15 kcal/kg FFM/d. This will be followed by a minimum 3-week washout period where the participant will be advised to return to their routine diet and exercise.
Other: Diet-induced low energy availability
A 6-day severe low energy availability (LEA, 15kcal/kg FFM/d) trial, achieved by superimposing increased exercise energy expenditure on the HEA trial. Energy intake will be 45 kcal/kg FFM/d and exercise energy expenditure will be 30 kcal/kg FFM/d. This will be followed by a minimum 3-week washout period where the participant will be advised to return to their routine diet and exercise.
Other: Exercise-induced low energy availability
6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing restricted energy intake on the control trial.
6-days of severe low energy availability (LEA, 15kcal/kg FFM/d), achieved by superimposing increased exercise energy expenditure on the control trial.
Sleeping metabolic rate between trials, measured using a human metabolic chamber on night 5 of each trial condition.
The primary outcome is the within-participant and sex-based difference in Sleeping Metabolic Rate (SMR) across the three trial conditions. Analyses will also compare differences in SMR responses between sexes.
Time frame: Night 5 of each trial condition from enrolment to the end of the third trial period.
Fasting values of metabolic and reproductive hormones between trials.
Within-participant and sex-based changes in fasting values of metabolic and reproductive hormones (testosterone, estrogen, progesterone, IGF-1, T3, leptin, iron status, lipids, glucose/insulin). Measured via venous blood sample on day 1 and day 5 of each trial.
Time frame: Day 1 of each trial condition from enrollment to Day 5 of the third trial period.
Overnight pulsatility of luteinising hormone between trials.
The secondary outcome is within-participant and sex-based difference in overnight pulsatility of luteinising hormone. This will be measured via venous blood samples taken every 15 minutes for 8 hours on night 4 of each trial.
Time frame: Night 4 of each trial condition from enrolment to Day 5 of the third trial period.
Overnight pulsatility of growth hormone between trials.
The secondary outcome is within-participant and sex-based difference in overnight pulsatility of growth hormone. This will be measured via venous blood samples taken every 15 minutes for 8 hours on night 4 of each trial.
Time frame: Night 4 of each trial condition from enrolment to Day 5 of the third trial period.
Overnight pulsatility of cortisol between trials.
The secondary outcome is within-participant and sex-based difference in overnight pulsatility of cortisol. This will be measured via venous blood samples taken every 15 minutes for 8 hours on night 4 of each trial.
Time frame: Night 4 of each trial condition from enrolment to Day 5 of the third trial period.
Dietary iron absorption and regulation between trials.
Within-participant and sex-based change in dietary iron absorption and regulation (plasma iron-isotope (Fe57) appearance), measured via blood sample collected 0-480minutes and at 28 days after intake of stable isotope Fe57.
Time frame: Night 4 of each trial from enrolment, to 28 days post the third trial period.
Substrate utilisation during a standardised exercise protocol between trials.
Within-participant and sex-based change in substrate utilisation, during a standardised exercise protocol between trials. This will be measured by venous and capillary blood samples on Day 5 of each trial.
Time frame: Day 5 of each trial condition from enrolment to Day 5 of the third trial period.
Abundance of naturally occurring isotopes of calcium in urine between trials.
Within-participant and sex-based change in abundance of naturally occurring isotopes of calcium (40Ca, 42Ca, 43Ca, 44Ca, 46Ca, and 48Ca) in urine, to predict boen metabolism. This will be measured via first void urine samples collected on days 1 and 4, and 24-hour urine collection on days 5-6 of each trial.
Time frame: Days 1, 4, 5 and 6 of each trial condition from enrolment to Day 6 of the third trial period.
Immune markers between trials.
Within-participant and sex-based difference in immune markers (IL-6, mitochondrial respiration, reactive oxygen species emission and protein expression in peripheral blood mononuclear cells (PBMCs), circulating leukocyte type distribution and mobilisation, circulating cell-free DNA). This will be measured via blood sample on day 5 of each trial.
Time frame: Day 5 of each trial, from enrolment to day 5 of the third trial period.
Whole-body protein turnover and muscle proteolysis between trials.
Within-participant and sex-based difference in whole-body protein turnover (measured as 15N-Alanine) and muscle proteolysis. This will be measured via 24-hour urine collection on days 5-6.
Time frame: Days 5-6 of each trial condition from enrolment to the end of the third trial period.
Cognitive control between trials.
Within-participant and sex-based change in cognitive control assessed via the 3-minute Simon Squared, delivered via Inquisit software. This will be measured on days 1 and 6 of each trial.
Time frame: Days 1 and 6 of each trial condition from enrolment to day 6 of the third trial period.
Cognitive arousal between trials.
Within-participant and sex-based change in cognitive arousal, assessed via the 5 minute psychomotor vigilance test, delivered via Inquisit software. This will be measured on days 1 and 6 of each trial.
Time frame: Days 1 and 6 of each trial condition from enrolment to day 6 of the third trial period.
Semi-targeted lipidomics between trials.
Within participant and sex-based difference in lipidomics measured via venous blood sample on day 5 of each trial.
Time frame: Day 5 of each trial condition from enrolment to day 5 of the third trial period.
Interstitial fluid glucose levels between trials.
Within-participant and sex-based difference of interstitial glucose levels between trials. This will be measured using continuous glucose monitors worn from day 1 to day 6 of each trial condition.
Time frame: Days 1-6 of each trial condition from enrolment to the end of day 6 of the third trial period.
Duration of sleep stages between trials.
Within-participant and sex-based difference in duration (minutes) of sleep stages per night on nights 3-5 of each trial period, measured using the Somfit wearable device.
Time frame: Nights 3-5 of each trial condition from enrolment to day 6 of the third trial period.
Sleep quantity between trials.
Within-participant and sex-based difference in sleep quantity (total sleep time) measured using the Oura Ring wearable device on nights 1-5 throughout the trial periods.
Time frame: Nights 1-5 of each trial condition from enrolment to day 6 of the third trial period.
Sleep onset time between trials.
Within-participant and sex-based difference in sleep onset time on nights 3-5 of each trial period, measured using the Somfit wearable device and Oura Ring.
Time frame: Nights 3-5 of each trial condition from enrolment to day 6 of the third trial period.
Sleep offset time between trials.
Within-participant and sex-based difference in sleep offset time on nights 3-5 of each trial period, measured using the Somfit wearable device and Oura Ring.
Time frame: Nights 3-5 of each trial condition from enrolment to day 6 of the third trial period.
Sleep onset latency between trials.
Within-participant and sex-based difference in sleep onset latency on nights 3-5 of each trial period, measured using the Somfit wearable device.
Time frame: Nights 3-5 of each trial condition from enrolment to day 6 of the third trial period.
Rapid eye movement (REM) onset latency between trials.
Within-participant and sex-based difference in REM onset latency on nights 3-5 of each trial period, measured using the Somfit wearable device.
Time frame: Nights 3-5 of each trial condition from enrolment to day 6 of the third trial period.
Number of awakenings per night between trials.
Within-participant and sex-based difference in number of awakenings per night on nights 3-5 of each trial period, measured using the Somfit wearable device.
Time frame: Nights 3-5 of each trial condition from enrolment to day 6 of the third trial period.
Sleep quality between trials.
Within-participant and sex-based difference in sleep quality (total sleep time as a percentage of time in bed) measured using the Oura Ring wearable device on nights 1-5 throughout the trial periods.
Time frame: Nights 1-5 of each trial condition from enrolment to day 6 of the third trial period.
Plan to share: Yes — The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
Time frame: For a period of 36 months from publication of the primary outcome.
Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Relative Energy Deficiency in Sport →
Australian Catholic University